Healthcare Industry News: joint replacement
News Release - May 31, 2017
Hyalex Orthopaedics Raises $16 Million Series A Financing and Appoints Chief Executive OfficerBOSTON, May 31, 2017 -- (Healthcare Sales & Marketing Network) -- Hyalex Orthopaedics, a medical device company advancing new products that feature HYALEX™ technology, a synthetic polymer that mimics cartilage, today announced it has raised $16 million in Series A financing. The financing was led by Canaan Partners, with participation from Osage University Partners and Johnson & Johnson Innovation – JJDC Inc. (JJDC).
"Backed by a body of scientific research and a leadership team with over 10 years of experience in orthopedics, Hyalex is poised to develop an innovative approach to treat osteoarthritis (OA) by replacing cartilage in joint surgery," said Wende Hutton, general partner for Canaan Partners and a newly-appointed board member for Hyalex. "While joint replacement surgery is a viable option for many patients experiencing joint degeneration, younger patients may encounter some limitations in mobility and face future joint revisions. A less invasive approach to treat osteoarthritis has significant potential and is needed to help these patients live full, active lives."
Incorporating technology licensed from Stanford University, Hyalex has developed a breakthrough synthetic biomaterial with properties that mimic the structure and function of the hyaline cartilage that lines articulating joints, such as the hip, knee, shoulder and ankle. "The technology offers the ability to maintain an extremely low wear profile even at high loads," said Lampros Kourtis, Ph.D., Hyalex's co-founder and chief technology officer. "Our vision is to leverage HYALEX's unique mechanical, friction, and wear properties to replace arthritic cartilage while sparing healthy bone."
Concurrent with the financing, Mira Sahney was appointed president and CEO of Hyalex Orthopaedics. In addition to Ms. Hutton, Bill Harrington, managing partner of Osage University Partners and Renee Ryan, vice president, venture investments, JJDC will join Hyalex's board of directors.
Mira Sahney has over 20 years of diversified global corporate experience including leadership of sales, marketing and R&D organizations. Prior to joining Hyalex, Ms. Sahney served as senior vice president and general manager at Smith & Nephew where she led the growth and sale of the gynecology division to Medtronic for $350 million and the turnaround of the ENT division.
"The HYALEX polymer has the potential to replace damaged cartilage in joints, creating the opportunity for a less invasive, more anatomic solution in disease states such as osteoarthritis or cartilage injuries," said Ms. Sahney. "We are seeking to use this technology to improve standard of care for the approximate three million joint replacement procedures annually worldwide, particularly for younger patients who seek long active lives following their surgeries."
About Hyalex Orthopaedics
Hyalex Orthopaedics is a Boston-based medical device start-up focused on developing and commercializing new products that feature HYALEX™ materials technology. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. HYALEX Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.
About Mira Sahney
Mira Sahney is the president and CEO of Hyalex Orthopaedics. Prior to joining Hyalex, Ms. Sahney was the senior vice president and general manager of the ENT and Gynecology divisions at Smith & Nephew. Prior to Smith & Nephew, she was president and co-founder of an award-winning start-up, Myomo, Inc.. She graduated from the MIT Leaders for Global Operations (LGO) program with an MBA from the MIT Sloan School of Management and an MS in mechanical engineering. Additionally, she holds an MS from Stanford University and a BSE from the University of Michigan.
Source: Hyalex Orthopaedics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.